Quantitative Investment Management LLC Invests $2.23 Million in Becton, Dickinson and Company $BDX

Quantitative Investment Management LLC purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) in the second quarter, HoldingsChannel.com reports. The fund purchased 14,751 shares of the medical instruments supplier’s stock, valued at approximately $2,232,000.

A number of other large investors have also recently bought and sold shares of BDX. Auto Owners Insurance Co raised its position in shares of Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after buying an additional 40,528,680 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $3,721,533,000. State Street Corp increased its stake in Becton, Dickinson and Company by 0.8% in the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock valued at $2,714,871,000 after acquiring an additional 116,737 shares during the last quarter. First Eagle Investment Management LLC raised its position in Becton, Dickinson and Company by 16.5% during the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock valued at $2,260,139,000 after purchasing an additional 1,651,592 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Becton, Dickinson and Company by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 6,885,361 shares of the medical instruments supplier’s stock worth $1,331,165,000 after purchasing an additional 53,884 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 9,105 shares of company stock valued at $1,590,208. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.7%

Shares of BDX stock opened at $188.13 on Tuesday. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $193.07. The stock’s fifty day simple moving average is $167.10 and its 200 day simple moving average is $160.32. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $51.84 billion, a P/E ratio of 56.67, a P/E/G ratio of 13.36 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the firm posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on BDX shares. Royal Bank Of Canada lifted their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Bank of America lifted their target price on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Monday. Evercore set a $180.00 target price on Becton, Dickinson and Company in a research note on Monday, July 6th. Wells Fargo & Company increased their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $187.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.